Početna › Rabdomiosarkom
Kliničke studije za Rabdomiosarkom koje traže sudionike u SAD-u
26 studija za Rabdomiosarkom traži sudionike na lokacijama širom Sjedinjenih Američkih Država.
Gradovi s najviše studija
- Houston, TX6 studija
- Memphis, TN6 studija
- Washington, DC5 studija
- Boston, MA4 studija
- Salt Lake City, UT4 studija
- Philadelphia, PA4 studija
- Seattle, WA3 studija
- Aurora, CO3 studija
- Dallas, TX3 studija
- Birmingham, AL3 studija
- The Bronx, NY3 studija
- Baltimore, MD3 studija
Po državama
- Alabama3 studija
- Colorado3 studija
- Distrikt Columbia4 studija
- Florida3 studija
- Kalifornija7 studija
- Maryland4 studija
- Massachusetts4 studija
- New York4 studija
- Ohio5 studija
- Pennsylvania5 studija
- Tennessee8 studija
- Texas9 studija
- Utah4 studija
- Washington3 studija
Nedavno ažurirane studije
Službeni tekst studije (engleski)
FGFR4 Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory Rhabdomyosarcoma
U tijeku regrutacijaFaza 1
Od 3 do 39 godina · Oba spola · Ažurirano 29. ruj 2026. · NCT06865664Phase I Trial to Determine the Dose and Evaluate the PK and Safety of Lutetium Lu 177 Edotreotide Therapy in Pediatric Participants With SSTR-positive Tumors
U tijeku regrutacijaFaza 1
24 Months – 18 Years · Oba spola · Ažurirano 25. ruj 2026. · NCT06441331Silmitasertib (CX-4945) in Combination With Chemotherapy for Relapsed Refractory Solid Tumors
U tijeku regrutacijaFaza 1/2
Do 30 godina · Oba spola · Ažurirano 3. ruj 2026. · NCT06541262A Study Comparing Higher Dose Chemotherapy Over a Shorter Amount of Time to Lower Dose Chemotherapy Plus Maintenance Over a Longer Amount of Time in Patients With Newly Diagnosed Intermediate-Risk Rhabdomyosarcoma (IR RMS)
U tijeku regrutacijaFaza 3
Do 50 godina · Oba spola · Ažurirano 25. kol 2026. · NCT07466316Integration of Adaptive Proton Therapy in Pediatric Solid Tumors and Hodgkin's Lymphoma
U tijeku regrutacija
Sve dobne skupine · Oba spola · Ažurirano 21. kol 2026. · NCT07514819Selective Antigen Specific T Cells and CAR T Cells in Subjects With Relapsed/Refractory Embryonal Tumors (SABRE)
U tijeku regrutacijaFaza 1
Od 1 do 23 godina · Oba spola · Ažurirano 13. kol 2026. · NCT07172958Disulfiram With Copper Gluconate and Liposomal Doxorubicin in Treatment-Refractory Sarcomas
U tijeku regrutacijaFaza 1
Od 18 godina i više · Oba spola · Ažurirano 6. kol 2026. · NCT05210374Interleukin-15 and -21 Armored Glypican-3-specific Chimeric Antigen Receptor Expressed in T Cells for Pediatric Solid Tumors
U tijeku regrutacijaFaza 1
Od 1 do 21 godina · Oba spola · Ažurirano 6. kol 2026. · NCT04715191Feasibility Study on the Effect of a Methionine-Reduced Diet on Serum Levels in Pts w/ Solid Tumors
U tijeku regrutacijaRana faza 1
Od 18 godina i više · Oba spola · Ažurirano 31. srp 2026. · NCT07628634PEEL-224, Vincristine and Temozolomide in Pediatric Solid Tumors
U tijeku regrutacijaFaza 1/2
Od 1 do 30 godina · Oba spola · Ažurirano 22. srp 2026. · NCT06721689Targeted Oligometastatic Radiation in Pediatric and Young Adult Patients With Soft Tissue and Bone Sarcoma
U tijeku regrutacija
Do 39 godina · Oba spola · Ažurirano 13. srp 2026. · NCT06796543Alpha/Beta T and B Cell Depletion With Zoledronic Acid for Solid Tumors
U tijeku regrutacijaFaza 1/2
6 Months – 25 Years · Oba spola · Ažurirano 30. lip 2026. · NCT06625190Familial Investigations of Childhood Cancer Predisposition
U tijeku regrutacijaOpažajna studija
Sve dobne skupine · Oba spola · Ažurirano 17. lip 2026. · NCT03050268Treatment of Newly Diagnosed Rhabdomyosarcoma Using Molecular Risk Stratification and Liposomal Irinotecan Based Therapy in Children With Intermediate and High Risk Disease
U tijeku regrutacijaFaza 2
Do 22 godina · Oba spola · Ažurirano 15. lip 2026. · NCT06023641VITAS: Atezolizumab in Combination With Chemotherapy for Pediatric Relapsed/Refractory Solid Tumors
U tijeku regrutacijaFaza 1/2
6 Months – 30 Years · Oba spola · Ažurirano 2. lip 2026. · NCT04796012B7-H3-Specific Chimeric Antigen Receptor Autologous T-Cell Therapy for Pediatric Patients With Solid Tumors (3CAR)
U tijeku regrutacijaFaza 1
Do 21 godina · Oba spola · Ažurirano 19. svi 2026. · NCT04897321Study of Onivyde With Talazoparib or Temozolomide in Children With Recurrent Solid Tumors and Ewing Sarcoma
U tijeku regrutacijaFaza 1/2
12 Months – 30 Years · Oba spola · Ažurirano 19. svi 2026. · NCT04901702Vorinostat in Combination With Chemotherapy in Relapsed/Refractory Solid Tumors and CNS Malignancies
U tijeku regrutacijaFaza 1
Od 1 do 30 godina · Oba spola · Ažurirano 15. tra 2026. · NCT04308330Reduced Intensity Haploidentical BMT for High Risk Solid Tumors
U tijeku regrutacijaFaza 2
Od 1 do 50 godina · Oba spola · Ažurirano 13. ožu 2026. · NCT01804634Phase 1/2 Trial to Evaluate the Safety and Efficacy of PEEL-224 in Combination With Vincristine and Temozolomide in Adolescents and Young Adults With Relapsed or Refractory Sarcomas
U tijeku regrutacijaFaza 1/2
Od 12 do 49 godina · Oba spola · Ažurirano 19. velj 2026. · NCT06709495Immunotherapy for Solid Tumor Malignancies in Pediatrics Using Interleukin-15 and -21 Armored Glypican-3-specific Chimeric Antigen Receptor T Cells
U tijeku regrutacijaFaza 1
Od 1 do 26 godina · Oba spola · Ažurirano 17. velj 2026. · NCT07148050HER2 Chimeric Antigen Receptor (CAR) T Cells in Combination With Checkpoint Blockade in Patients With Advanced Sarcoma
U tijeku regrutacijaFaza 1
Od 1 do 25 godina · Oba spola · Ažurirano 22. sij 2026. · NCT04995003Molecular Analysis Of Solid Tumors
U tijeku regrutacijaOpažajna studija
Do 25 godina · Oba spola · Ažurirano 12. stu 2025. · NCT01050296Immunotherapy For Adults With GPC3-Positive Solid Tumors Using IL-15 and IL-21 Armored GPC3-CAR T Cells
U tijeku regrutacijaFaza 1
Do 21 godina · Oba spola · Ažurirano 3. stu 2025. · NCT06198296Alpha/Beta CD19+ Depleted Haploidentical Transplantation + Zometa for Pediatric Hematologic Malignancies and Solid Tumors
U tijeku regrutacijaFaza 1
7 Months – 21 Years · Oba spola · Ažurirano 16. lis 2025. · NCT02508038Iz ClinicalTrials.gov, podaci preuzeti 4. lis 2026.. Svaka studija ima svoje uvjete prihoda; tim studije odlučuje tko se može priključiti.